DK168667B1 - Monoklonale antistoffer, der genkender et kerneprotein fra det lymfadenopatiassocierede virus (LAV), hybridomer, der udskiller disse antistoffer, og fremgangsmåde til påvisning eller rensning af kerneproteinet - Google Patents
Monoklonale antistoffer, der genkender et kerneprotein fra det lymfadenopatiassocierede virus (LAV), hybridomer, der udskiller disse antistoffer, og fremgangsmåde til påvisning eller rensning af kerneproteinet Download PDFInfo
- Publication number
- DK168667B1 DK168667B1 DK450986A DK450986A DK168667B1 DK 168667 B1 DK168667 B1 DK 168667B1 DK 450986 A DK450986 A DK 450986A DK 450986 A DK450986 A DK 450986A DK 168667 B1 DK168667 B1 DK 168667B1
- Authority
- DK
- Denmark
- Prior art keywords
- lav
- monoclonal antibodies
- polypeptide
- protein
- hybridomas
- Prior art date
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 20
- 208000008771 Lymphadenopathy Diseases 0.000 title claims abstract description 5
- 208000018555 lymphatic system disease Diseases 0.000 title claims abstract description 5
- 241000700605 Viruses Species 0.000 title claims description 16
- 238000000034 method Methods 0.000 title claims description 15
- 101710132601 Capsid protein Proteins 0.000 title abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 27
- 229920001184 polypeptide Polymers 0.000 claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims abstract 3
- 102100029008 Putative HTLV-1-related endogenous sequence Human genes 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 102100029807 SUMO-conjugating enzyme UBC9 Human genes 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 230000003248 secreting effect Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 2
- 102000007999 Nuclear Proteins Human genes 0.000 claims 1
- 108010089610 Nuclear Proteins Proteins 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 3
- 102100036089 Fascin Human genes 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000012286 ELISA Assay Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 101800002723 p18 Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 102100038980 Exosome complex component CSL4 Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 101800001476 Viral genome-linked protein Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000001254 nonsecretory effect Effects 0.000 description 1
- 101800000605 p13 Proteins 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- AIDS & HIV (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB858501473A GB8501473D0 (en) | 1985-01-21 | 1985-01-21 | Cloned dna sequences |
GB8501473 | 1985-01-21 | ||
PCT/EP1986/000018 WO1986004336A1 (fr) | 1985-01-21 | 1986-01-21 | Anticorps monoclonaux contre les proteines de noyau de virus associes aux lymphadenopathies |
EP8600018 | 1986-01-21 |
Publications (3)
Publication Number | Publication Date |
---|---|
DK450986D0 DK450986D0 (da) | 1986-09-19 |
DK450986A DK450986A (da) | 1986-09-19 |
DK168667B1 true DK168667B1 (da) | 1994-05-16 |
Family
ID=10573161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK450986A DK168667B1 (da) | 1985-01-21 | 1986-09-19 | Monoklonale antistoffer, der genkender et kerneprotein fra det lymfadenopatiassocierede virus (LAV), hybridomer, der udskiller disse antistoffer, og fremgangsmåde til påvisning eller rensning af kerneproteinet |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0211022B1 (fr) |
JP (1) | JPS62502095A (fr) |
KR (1) | KR950008570B1 (fr) |
AT (1) | ATE51876T1 (fr) |
AU (1) | AU600227B2 (fr) |
DE (1) | DE3670294D1 (fr) |
DK (1) | DK168667B1 (fr) |
GB (1) | GB8501473D0 (fr) |
OA (1) | OA08413A (fr) |
WO (1) | WO1986004336A1 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217861A (en) * | 1983-09-15 | 1993-06-08 | Institut Pasteur | Antigen of a human retrovirus, namely p18 protein of human immunodeficiency virus (HIV), compositions containing the antigen, a diagnostic method for detecting acquired immune deficiency syndrome (AIDS) and pre-AIDS and a kit therefor |
US5173400A (en) * | 1983-09-15 | 1992-12-22 | Institut Pasteur | Antibody detection of antibodies to viral proteins in serum |
US5374519A (en) * | 1983-12-05 | 1994-12-20 | Institut Pasteur | Oligopeptides comprising p18 protein of human immunodeficiency virus (HIV), compositions comprising peptides of p18 protein of HIV, and diagnostic kits and methods for detecting acquired immune deficiency syndrome (AIDS) |
DE3650011T2 (de) * | 1985-04-08 | 1994-11-17 | Genetic Systems Corp | EXPRESSION UND DIAGNOSE MIT gag-KODIERTEN PEPTIDEN, DIE MIT ANTIKÖRPERN GEGEN LAV IMMUNOLOGISCH REAKTIV SIND. |
DE3650175T3 (de) | 1985-04-29 | 2007-09-06 | Bio-Rad Laboratories, Inc., Hercules | Synthetische antigene zum nachweis von aids. |
GR862412B (en) * | 1985-09-25 | 1987-01-23 | Oncogen | Vaccines and immuinoassays for acquired immune deficiency syndrome |
FR2593519B1 (fr) * | 1985-09-25 | 1994-01-07 | Oncogen | Vaccin contre le syndrome immunodeficitaire acquis et intermediaires pour la preparation de ce vaccin |
JPS63501716A (ja) * | 1985-10-24 | 1988-07-14 | サウスウエスト・ファウンデ−ション・フォア・バイオメディカル・リサ−チ | 合成ペプチドおよびaidsおよびarcの診断ならびにワクチン注射へのその使用 |
US6130314A (en) * | 1986-03-26 | 2000-10-10 | Genetic Systems Corporation | Synthetic antigen for the detection of AIDS-related disease |
US4904581A (en) * | 1986-05-06 | 1990-02-27 | Epitope, Inc. | Method of detecting AIDS virus infection |
NZ221440A (en) * | 1986-08-20 | 1991-11-26 | Genetic Systems Corp | Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections |
US5166050A (en) * | 1986-08-20 | 1992-11-24 | Bristol-Myers Squibb Company | Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections |
DE3636540A1 (de) * | 1986-10-27 | 1988-04-28 | Behringwerke Ag | Verfahren zur bestimmung von anti-hiv, mittel dazu und ihre verwendung in diesem verfahren |
CA1341277C (fr) * | 1987-03-16 | 2001-07-31 | Roland Keith Mcgready | Anticorps anti-paratopique et son procede de fabrication |
AU625720B2 (en) * | 1987-05-01 | 1992-07-16 | Genetic Systems Corporation | Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use |
CA1339363C (fr) * | 1987-05-01 | 1997-08-26 | Alan Ray Flesher | Anticorps monoclonaux pour des regions antigeniques specifiques du virus de l'immunodeficience humaine; methodes d'utilisation |
US4888290A (en) * | 1987-11-06 | 1989-12-19 | Coulter Corporation | Monoclonal antibody specific to HIV antigens |
AU612760B2 (en) * | 1987-11-06 | 1991-07-18 | Coulter Corporation | Enzyme immunoassay for detecting hiv antigens in human sera |
EP0339504A3 (fr) * | 1988-04-26 | 1990-09-12 | The Du Pont Merck Pharmaceutical Company | Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères |
FR2632310B1 (fr) * | 1988-06-06 | 1992-04-10 | Pasteur Institut | Peptides ayant des proprietes protectrices d'un virus pathogene du type hiv dans des cellules sensibles |
DK580789D0 (da) * | 1989-11-20 | 1989-11-20 | Novo Nordisk As | Fremgangsmaade til oprensning af polypeptider |
CA2059317A1 (fr) * | 1991-01-15 | 1992-07-16 | Yi Zeng | Essai immunoenzymatique pour la detection des anticorps diriges contre le vih-1 |
US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA783261B (en) * | 1977-06-15 | 1979-06-27 | Wistar Inst | Method of producing antibodies |
JPS5939832A (ja) * | 1982-08-28 | 1984-03-05 | Ajinomoto Co Inc | モノクロ−ナル抗体ならびにその製法、使用法 |
GB8324800D0 (en) * | 1983-09-15 | 1983-10-19 | Pasteur Institut | Antigens |
-
1985
- 1985-01-21 GB GB858501473A patent/GB8501473D0/en active Pending
-
1986
- 1986-01-21 DE DE8686900767T patent/DE3670294D1/de not_active Expired - Lifetime
- 1986-01-21 JP JP61500764A patent/JPS62502095A/ja active Pending
- 1986-01-21 WO PCT/EP1986/000018 patent/WO1986004336A1/fr active IP Right Grant
- 1986-01-21 AU AU53200/86A patent/AU600227B2/en not_active Expired
- 1986-01-21 AT AT86900767T patent/ATE51876T1/de not_active IP Right Cessation
- 1986-01-21 KR KR1019860700648A patent/KR950008570B1/ko not_active IP Right Cessation
- 1986-01-21 EP EP86900767A patent/EP0211022B1/fr not_active Expired - Lifetime
- 1986-09-19 OA OA58957A patent/OA08413A/xx unknown
- 1986-09-19 DK DK450986A patent/DK168667B1/da not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
GB8501473D0 (en) | 1985-02-20 |
OA08413A (en) | 1988-06-30 |
DK450986D0 (da) | 1986-09-19 |
EP0211022B1 (fr) | 1990-04-11 |
JPS62502095A (ja) | 1987-08-20 |
KR870700073A (ko) | 1987-02-28 |
ATE51876T1 (de) | 1990-04-15 |
WO1986004336A1 (fr) | 1986-07-31 |
DE3670294D1 (de) | 1990-05-17 |
EP0211022A1 (fr) | 1987-02-25 |
KR950008570B1 (ko) | 1995-08-03 |
AU5320086A (en) | 1986-08-13 |
DK450986A (da) | 1986-09-19 |
AU600227B2 (en) | 1990-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK168667B1 (da) | Monoklonale antistoffer, der genkender et kerneprotein fra det lymfadenopatiassocierede virus (LAV), hybridomer, der udskiller disse antistoffer, og fremgangsmåde til påvisning eller rensning af kerneproteinet | |
JP2752329B2 (ja) | リンパ節症及び後天性免疫不全症候群のウイルスのエンベロープ抗原の製造方法 | |
Earl et al. | Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities | |
Papsidero et al. | Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping | |
US5166050A (en) | Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections | |
JPH02160800A (ja) | ヒト免疫不全ウイルス(HIV)env‐コードペプチド | |
JP2958346B2 (ja) | 抗HIV―2モノクローナル抗体およびそれを用いた抗HIV―2gp41抗体の検出方法 | |
IE872219L (en) | Treatment of hiv infections | |
EP0492560B1 (fr) | Anticorps monoclonaux humains contre la glycoprotéine transmembranaire (gp41) de HIV-1, et peptides associés | |
US6171596B1 (en) | Oligomeric HIV-1 envelope glycoproteins | |
EP0581353A1 (fr) | Anticorps monoclonaux dirigés contre HIV-1 gp120, lignées cellulaires les produisant et structures epitopiques correspondantes | |
Robert-Guroff et al. | A monoclonal antibody specific for a 52,000-molecular-weight human T-cell leukemia virus-associated glycoprotein expressed by infected cells | |
US6039957A (en) | Oligomeric HIV-1 envelope glycoproteins | |
JPS62500592A (ja) | リンパ節症及び後天性免疫不全症候群のウイルスの抗原,特にエンベロ−プ抗原,及びウイルス,ウイルスエンベロ−プ抗原の産生方法,免疫原組成物の調製用叉は該ウイルスに対する抗体の存在の診断用としての該抗原の | |
EP0448095A1 (fr) | Sous-région de la protéine ENV rétrovirale, séquences d'ADN codant pour celle-ci et compositions pour le diagnostic, la prévention ou la thérapie des infections rétrovirales | |
Krust et al. | Characterization of a monoclonal antibody specific for the HIV-1 precursor glycoprotein | |
US5407811A (en) | Monoclonal antibodies to GP110 of HIV and hybridomas secreting these antibodies | |
CN116042531B (zh) | 抗猪δ冠状病毒NS7和NS7a蛋白的杂交瘤细胞株、单克隆抗体及其应用 | |
WO1996027012A1 (fr) | Antigenes specifiques du vih-1, groupe o | |
REEVES et al. | Mouse monoclonal antibodies to human immunodeficiency virus glycoprotein 120 generated by repeated immunization with glycoprotein 120 from a single isolate, or by sequential immunization with glycoprotein 120 from three isolates | |
KR100254811B1 (ko) | 인간 면역결핍 바이러스의 덮개 단백질인 p24 에 대한 단일클론항체, 이를 생산하는 융합세포주 및 그의 제조방법 | |
KR100250833B1 (ko) | 인간 면역결핍 바이러스-1의 표면 단백질 지피41에 대한 단일클론 항체, 이를 생산하는 융합세포주및 그의 제조방법 | |
Orlik et al. | Two immunodominant regions revealed by monoclonal antibodies on the main structural protein p24 of bovine leukemia virus | |
Larcher et al. | Characterization of monoclonal antibodies to human immunodefiency virus type 1 gp41 by HIV-1 polypeptides expressed in Escherichia coli | |
Qureshi et al. | Identification and production of monoclonal antibodies against a discriminating protein molecule between B and D variants of encephalomyocarditis virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B1 | Patent granted (law 1993) | ||
PUP | Patent expired |